Out-of-
Cardiopulmonary resuscitation
First responder system
Out-of-hospital cardiac arrest
Smartphone alerting system
Journal
Resuscitation plus
ISSN: 2666-5204
Titre abrégé: Resusc Plus
Pays: Netherlands
ID NLM: 101774410
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
epublish
Résumé
Since 2021, international guidelines for cardiopulmonary resuscitation recommend the implementation of so-called "life-saving systems". These systems include smartphone alerting systems (SAS), which enable dispatch centres to alert first responders via smartphone applications, who are in proximity of a suspected out-of-hospital cardiac arrest (OHCA). However, the effect of SAS on survival remains unknown. The aim is to assess the rate of survival to hospital discharge in adult patients with OHCA not witnessed by emergency medical services (EMS): before and after SAS implementation. Multicentre, prospective, observational, intention-to-treat, pre-post design clinical trial. Adults (aged ≥ 18 years), OHCA not witnessed by EMS, no traumatic cause for cardiac arrest, cardiopulmonary resuscitation initiated or continued by EMS. Dispatch-centre-based. Primary: survival to hospital discharge. Secondary: time to first compression, rate of basic life support measures before EMS arrival, rate of patients with shockable rhythm at EMS arrival, Cerebral Performance Category at hospital discharge, and duration of hospital stay. Assuming an absolute difference in survival rates to hospital discharge of 4% in the two groups (11% before implementation of the SAS versus 15% after) and 80% power, and a type 1 error rate of 0.05, the required sample size is The HEROES trial will investigate the effects of a SAS on the survival rate after OHCA. German Clinical Trials Register (DRKS, ID: DRKS00032920).
Sections du résumé
Background
UNASSIGNED
Since 2021, international guidelines for cardiopulmonary resuscitation recommend the implementation of so-called "life-saving systems". These systems include smartphone alerting systems (SAS), which enable dispatch centres to alert first responders via smartphone applications, who are in proximity of a suspected out-of-hospital cardiac arrest (OHCA). However, the effect of SAS on survival remains unknown.
Aim
UNASSIGNED
The aim is to assess the rate of survival to hospital discharge in adult patients with OHCA not witnessed by emergency medical services (EMS): before and after SAS implementation.
Design
UNASSIGNED
Multicentre, prospective, observational, intention-to-treat, pre-post design clinical trial.
Population
UNASSIGNED
Adults (aged ≥ 18 years), OHCA not witnessed by EMS, no traumatic cause for cardiac arrest, cardiopulmonary resuscitation initiated or continued by EMS.
Setting
UNASSIGNED
Dispatch-centre-based.
Outcomes
UNASSIGNED
Primary: survival to hospital discharge. Secondary: time to first compression, rate of basic life support measures before EMS arrival, rate of patients with shockable rhythm at EMS arrival, Cerebral Performance Category at hospital discharge, and duration of hospital stay.
Sample size
UNASSIGNED
Assuming an absolute difference in survival rates to hospital discharge of 4% in the two groups (11% before implementation of the SAS versus 15% after) and 80% power, and a type 1 error rate of 0.05, the required sample size is
Conclusions
UNASSIGNED
The HEROES trial will investigate the effects of a SAS on the survival rate after OHCA.
Trial registration
UNASSIGNED
German Clinical Trials Register (DRKS, ID: DRKS00032920).
Identifiants
pubmed: 38328746
doi: 10.1016/j.resplu.2024.100564
pii: S2666-5204(24)00015-8
pmc: PMC10847368
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100564Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘MPM is chair of Region der Lebensretter e.V. (non-profit organisation), member of the executive committee of the German Resuscitation Council (GRC), shareholder of SmartResQ ApS, Denmark, and received speaker honoraria by Stryker. JG is board member of Region der Lebensretter e.V. HJB is vice chair of Region der Lebensretter e.V. GT is board member of Region der Lebensretter e.V., secretary of the GRC, and shareholder of Resuscitec GmbH, Freiburg, Germany. JSP is member of Region der Lebensretter e.V. and member of the executive committee of the GRC. All other authors have no conflicts of interest to declare’.